Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Akute Leukämie bei multiplem Myelom (1979)
    Springer
    Journal of molecular medicine 57 (1979), S. 769-777 
    Details
    ISSN: 1432-1440
    Keywords: Multiple myeloma ; Acute leukaemia ; Secondary neoplasia ; Life table method ; Multiples Myelom ; Akute Leukämie ; Zweitneoplasie ; Sterbetafelmethode
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Es werden die Ergebnisse einer Follow-up-Studie vorgelegt, in deren Rahmen insgesamt 112 Plasmozytom-Patienten maximal 11 Jahre lang unter klinischer Beobachtung standen. 3 Patienten entwickelten innerhalb des Beobachtungszeitraumes eine akute Leukämie. Hierbei handelte es sich um je einen Fall von akuter myeloblastischer Leukämie, myelomonozytärer Leukämie und Erythroleukämie. Zur Schätzung der Inzidenz von akuter Leukämie bei Ausgangsbefund Plasmozytom wird eine erweiterte Sterbetafelmethode benutzt. Aus unseren Daten erhielten wir hiermit als Wahrscheinlichkeit, daß bei einem Plasmozytompatienten irgendwann im weiteren Krankheitsverlauf eine akute Leukämie auftritt, die Zahl 5,9%. Dieses Ergebnis wird auf Grund einer ausführlichen methodischen Diskussion als Hinweis auf ein stark erhöhtes AL-Risiko bei Plasmozytom-Patienten gewertet. In einer Literaturübersicht werden wichtige Daten von 100 Fällen mit der Assoziation von Plasmozytom und akuter Leukämie zusammengestellt.
    Notes: Summary The results of a follow-up study of 112 patients with multiple myeloma are presented. Three of these patients developed acute leukaemia during the respective period of clinical observation (maximum: 11 years) — one case of acute myeloblastic leukaemia, myelomonocytic leukaemia and erythroleukaemia, myelomonocytic leukaemia and erythroleukaemia, respectively. For estimating the incidence of acute leukaemia in the presence of multiple myeloma an extended life table method was applied. On the basis of our data this method gave a probability of 5.9% for a patient to develop acute leukaemia at any time after the diagnosis of multiple myeloma. In a statistical discussion this result is considered to confirm the assumption of a highly increased AL-risk in patients with multiple myeloma. In a survey of the literature some important data of 100 cases with the association acute leukaemia — multiple myeloma are reported.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01478035
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma (1999)
    Springer
    Annals of hematology 78 (1999), S. 456-462 
    Details
    ISSN: 1432-0584
    Keywords: Key words PBPC mobilization ; CD34+ cells ; G-CSF ; Malignant lymphoma ; Multiple myeloma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  We retrospectively analyzed factors influencing PBPC mobilization during steady-state hematopoiesis in 52 patients with malignant lymphoma (n=35) or multiple myeloma (n=17) who received 77 cycles of G-CSF (12.5–50 μg G-CSF/kg/day). For 15 of these patients, the first mobilization cycle (12.5 μg G-CSF/kg/day) was followed by a second course with an increased dose of G-CSF (25 or 50 μg/kg/day). Leukapheresis was started on day 4, about 2 h after s.c. G-CSF administration, and repeated on 2–5 consecutive days. CD34+ cells were determined by flow cytometry in each apheresis product and in the peripheral blood prior to G-CSF administration, beginning on day 4. Colony assays were performed on cryopreserved samples prior to autografting. In the 15 patients receiving two mobilization cycles the higher G-CSF dose was associated with higher levels of CD34+ cells, a higher mean yield of CD34+ cells per apheresis (p〈0.05), and a higher percentage of successful (〉2×106 CD34+ cells/kg) collections (p=0.058). Patients with limited previous cytotoxic therapy (n=19, up to six cycles of a standard regimen such as CHOP and/or less than 20% marrow irradiation) who received a daily dose of 12.5 μg G-CSF/kg had higher levels of circulating CD34+ cells, a higher mean yield of CD34+ cells per apheresis (p〈0.05), and a higher percentage of successful collections (p〈0.05) compared with patients previously treated with more intensive radiochemotherapy (n=15). Ten of 20 patients (50%) who failed during the first cycle were successful during subsequent cycles with escalated doses of G-CSF. Trough levels of circulating CD34+ cells on day 4 were predictive for success or failure to achieve 〉2×106 CD34+ cells/kg, especially in heavily pretreated patients. In conclusion, a daily dose of 12.5 μg G-CSF/kg seems sufficient to mobilize PBPC during steady-state hematopoiesis in the majority of patients who have received limited previous radiochemotherapy. Higher doses of G-CSF, up to 50 μg/kg/day, mobilize more PBPC and should be considered for patients previously treated with intensive radiochemotherapy or those failing to mobilize sufficient numbers of CD34+ cells with lower doses of G-CSF.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002770050598
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...